Vedolizumab-induced Bullous Pemphigoid: A Case Report with Serological Evidence and Mechanistic Insights
DOI:
https://doi.org/10.2340/actadv.v106.adv-2025-0090Keywords:
autoimmune bullous disorder, drug-associated bullous pemphigoid, VedolizumabDownloads
References
Bağcı IS, Horváth ON, Ruzicka T, Sárdy M. Bullous pemphigoid. Autoimmun Rev 2017; 16: 445–455 DOI: https://doi.org/10.1016/j.autrev.2017.03.010
Verheyden M, Murrell D, Bilgic A. 12871 A systematic review of drug-induced pemphigoid. J Am Acad Dermatol 2020; 83: AB113 DOI: https://doi.org/10.1016/j.jaad.2020.06.539
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699–710 DOI: https://doi.org/10.1056/NEJMoa1215734
Magdaleno-Tapial J, Ferrer-Guillén B, Valenzuela-Oñate C, Esteve-Martínez A. Acneiform eruption induced by vedolizumab. Dermatol Online J 2018; 24: 13030/qt0vg996xr. DOI: https://doi.org/10.5070/D32410041733
Sody E, Körber A. Psoriasis Induced by Vedolizumab. Inflamm Bowel Dis 2017; 23: E9–E11 DOI: https://doi.org/10.1097/MIB.0000000000001011
Odom MB, Chen JN, Echavarria JF, Gilson RT. A case of bullous pemphigoid in an ulcerative colitis patient treated with vedolizumab. JAAD Case Rep 2025; 66: 176–179 DOI: https://doi.org/10.1016/j.jdcr.2025.09.033
Settipane GA, Pudupakkam RK, McGowan JH. Corticosteroid effect on immunoglobulins. J Allergy Clin Immunol 1978; 62: 162–166 DOI: https://doi.org/10.1016/0091-6749(78)90101-X
Gorfu G, Rivera-Nieves J, Ley K. Role of beta7 integrins in intestinal lymphocyte homing and retention. Curr Mol Med 2009; 9: 836–850 DOI: https://doi.org/10.2174/156652409789105525
Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res 2010; 339: 269–280 DOI: https://doi.org/10.1007/s00441-009-0834-6
Aho S, Uitto J. Direct interaction between the intracellular domains of bullous pemphigoid antigen 2 (BP180) and beta 4 integrin, hemidesmosomal components of basal keratinocytes. Biochem Biophys Res Commun 1998; 243: 694–699. DOI: https://doi.org/10.1006/bbrc.1998.8162
Sedano R, Dhaliwal I, Ramsewak D, Jairath V. Drug-induced lupus associated with vedolizumab in a patient with Crohn’s disease. Inflamm Bowel Dis 2021; 27: e47–e48 DOI: https://doi.org/10.1093/ibd/izaa331
Licata G, Gambardella A, De Rosa A, Calabrese G, Alfano R, Argenziano G. Hidradenitis suppurativa caused by vedolizumab. Dermatitis 2021; 32: e23–e24 DOI: https://doi.org/10.1097/DER.0000000000000610
Choe SI, Bourgeois J, Nidamanuri S, Rubenzik R. Pyoderma gangrenosum in an ulcerative colitis patient on vedolizumab. Cureus 2024; 16: e69219 DOI: https://doi.org/10.7759/cureus.69219
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
